Spain fines drugmaker over €10 million for excessive pricing

Spain’s competition authority has become the latest enforcer to fine Leadiant Biosciences for abusing its dominance by overcharging its national health system for an orphan drug used to treat a rare metabolic disease.

Unlock unlimited access to all Global Competition Review content